India News | Proven Record for Safety, Says Bharat Biotech After Covaxin Gets Emergency Usage Nod for Kids Above 12 Yrs
Get latest articles and stories on India at LatestLY. Covaxin has a proven record for safety and efficacy from all the variants of COVID-19, said Bharat Biotech after its vaccine received emergency usage approval from the Drugs Controller General of India (DCGI) for kids aged between 12-18 years.
New Delhi [India], December 25 (ANI): Covaxin has a proven record for safety and efficacy from all the variants of COVID-19, said Bharat Biotech after its vaccine received emergency usage approval from the Drugs Controller General of India (DCGI) for kids aged between 12-18 years.
"Covaxin has established a proven record for safety and efficacy in adults for the original variant and subsequent variants," says the official release.
"Covaxin has established a proven record for safety and efficacy in adults for the original variant and subsequent variants. We have documented excellent safety and immunogenicity data readouts in Children," it added.
Bharat Biotech expressed gratitude to the Union Health Ministry, Drugs Controller General of India and National Technical Advisory Group on Immunisation "for their diligent review of all data and for their fastidious approval process."
Also Read | Coronavirus Vaccination for Children Aged 15-18 Years to Start From January 3, Announces PM Narendra Modi.
Bharat Biotech also thanked Prime Minister Narendra Modi, "for his visionary leadership during this pandemic." (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)